Medscape is available in 5 Language Editions – Choose your Edition here.


Thyroid Storm Treatment & Management

  • Author: Madhusmita Misra, MD, MPH; Chief Editor: Stephen Kemp, MD, PhD  more...
Updated: Jun 20, 2016

Approach Considerations

The approach to treatment of thyroid storm includes the following:

  • Supportive measures
  • Antiadrenergic drugs
  • Thionamides
  • Iodine preparations
  • Glucocorticoids
  • Bile acid sequestrants
  • Treatment of the underlying condition
  • Rarely plasmapheresis

Patients with contraindications to thionamides need to be managed with supportive measures, aggressive beta blockade, iodine preparations, glucocorticoids, and bile acid sequestrants for about a week in preparation for a thyroidectomy. Plasmapheresis may be attempted if other measures are not effective. 


Medical Care

Patients with thyroid storm should be treated in an ICU setting for close monitoring of vital signs and for access to invasive monitoring and inotropic support, if necessary. Initial stabilization and management of systemic decompensation is as follows:

  • Supportive measures
    • If needed, immediately provide supplemental oxygen, ventilatory support, and intravenous fluids. Dextrose solutions are the preferred intravenous fluids to cope with continuously high metabolic demand.
    • Correct electrolyte abnormalities.
    • Treat cardiac arrhythmia, if necessary.
    • Aggressively control hyperthermia by applying ice packs and cooling blankets and by administering acetaminophen (15 mg/kg orally or rectally every 4 hours).
  • Antiadrenergic drugs
    • Promptly administer antiadrenergic drugs (eg, propranolol) to minimize sympathomimetic symptoms. Propranolol is administered orally or via nasogastric tube at a dose of 60-80 mg every 4-6 hours and the dose adjusted based on heart rate and blood pressure. It may also be given intravenously when necessary for rapid onset of action (0.5-1 mg over 10 min followed by 1-2 mg over 10 min every few hours, adjusted based on vital signs). It is important to avoid propranolol in conditions such as asthma, chronic obstructive pulmonary disease, peripheral vascular disease, or decompensated heart failure. Cardioselective beta blockers such as atenolol or metoprolol may be administered in patients with reactive airway disease, and calcium channel blockers may be used when beta blockers are contraindicated. The use of intravenous short acting beta-1 blockers, such as esmolol (loading dose of 250-500 mcg/kg, followed by an infusion of 50-100 mcg/kg per minute), allows quick dose titration with minimization of side effects.
    • Dosing of beta blockers for thyroid storm in a pediatric population:
      • Propranolol: Neonates: 2 mg/kg per day PO/NGT divided every 6-12 hours; Children: 0.5-4 mg/kg per day PO/NGT divided every 6 hours (not to exceed 60 mg per day) or 0.01-0.02 mg/kg IV over 10 minutes (may repeat over 10’ every few hours to a maximum cumulative dose of 5 mg)
      • Esmolol: Loading dose: 250-500 mcg/kg over 1 minute, repeat as needed, maintenance dose: 50-100 mcg/kg per minute IV infusion
  • Thionamides: Correct the hyperthyroid state. Administer antithyroid medications to block further synthesis of thyroid hormones (THs).
    • High-dose propylthiouracil (PTU) is preferred over methimazole for treatment of severe thyroid storm because of its early onset of action and capacity to inhibit peripheral conversion of T4 to T3. Methimazole may be used in less severe cases. Dosing for thyroid storm in adults is as follows: PTU 200 mg every four hours or methimazole 20 mg orally every four to six hours; these drugs may need to be administered through a nasogastric tube.
    • Dosing of PTU for thyroid storm in children: Neonates: 5-10 mg/kg per day PO/NGT divided every 6-8 hours; Children: 15-20 mg/kg per day PO/NGT divided every 6-8 hours (up to 40 mg/kg per day has been used; not to exceed 1200 mg per day)
    • Of note, the US Food and Drug Administration (FDA) has added a boxed warning, the strongest warning issued by the FDA, to the prescribing information for PTU.
      • The boxed warning emphasizes the risk for severe liver injury and acute liver failure, some of which have been fatal. The boxed warning also states that PTU should be reserved for use in those who cannot tolerate other treatments such as methimazole, radioactive iodine, or surgery.
      • The decision to include a boxed warning was based on the FDA's review of postmarketing safety reports and meetings held with the American Thyroid Association, the National Institute of Child Health and Human Development, and the pediatric endocrine clinical community.
      • The FDA has identified 32 cases (22 adult and 10 pediatric) of serious liver injury associated with PTU. Among adults, 12 deaths and 5 liver transplants occurred; among the pediatric patients, 1 death and 6 liver transplants occurred. PTU is indicated for hyperthyroidism due to Graves disease. These reports suggest an increased risk for liver toxicity with PTU compared with methimazole. Serious liver injury has been identified with methimazole in 5 cases (3 resulting in death).
      • PTU is now considered as a second-line drug therapy for treatment of hyperthyroidism in general (though not thyroid storm), except in patients who are allergic or intolerant to methimazole, or women who are in the first trimester of pregnancy. Rare cases of embryopathy, including aplasia cutis, have been reported with methimazole during pregnancy. For more information, see the FDA Safety Alert.[11] The FDA recommends the following criteria be considered for prescribing PTU.
      • Reserve PTU use for during first trimester of pregnancy or for patients who are allergic to or intolerant of methimazole.
      • Closely monitor patients undergoing PTU therapy for signs and symptoms of liver injury, especially during the first 6 months after initiation of therapy.
      • For suspected liver injury, promptly discontinue PTU therapy and evaluate for evidence of liver injury and provide supportive care.
      • PTU should not be used in pediatric patients unless the patient is allergic to or intolerant of methimazole and no other treatment options are available.
      • Counsel patients to promptly contact their health care provider for the following signs or symptoms: fatigue, weakness, vague abdominal pain, loss of appetite, itching, easy bruising, or yellowing of the eyes or skin.
    • If the patient is given PTU during treatment of thyroid storm, this should be switched to methimazole at the time of discharge unless methimazole is contraindicated. If methimazole is contraindicated, alternative methods to treat hyperthyroidism should be considered after discharge, such as radioactive iodine or surgery.
  • Iodine compounds:
    • Administer iodine compounds (Lugol iodine or potassium iodide) orally or via a nasogastric tube to block the release of THs (at least 1 h after starting antithyroid drug therapy). In adults, SSKI is a given at a dose of 5 drops every 6 hours, or Lugol's iodine at a dose of 10 drops every 8 hours. If available, intravenous radiocontrast dyes such as ipodate and iopanoate can be effective in this regard. These agents are particularly effective at preventing peripheral conversion of T4 to T3.
    • Dosing of iodine compounds for thyroid storm in children:
      • SSKI (50 mg iodide per drop): Neonates: 2 drops PO/NGT every 6-8 hours; Children: 2-5 drops PO/NGT every 6 hours
      • Lugol's iodine (8 mg iodine/drop): 10 drops PO/NGT every 8 hours
  • Glucocorticoids
    • Administer glucocorticoids to decrease peripheral conversion of T4 to T3. This may also be useful in preventing relative adrenal insufficiency due to hyperthyroidism and improving vasomotor symptoms. Hydrocortisone is administered intravenously at a dose of 100 mg every 8 hours or dexamethasone at a dose of 1-2 mg every 6 hours. 
    • Dosing of glucocorticoids for thyroid storm in children:
      • Hydrocortisone: 5 mg/kg (up to 100 mg) intravenously every 6-8 hours
      • Dexamethasone: 0.1-0.2 mg/kg per day divided every 6-8 hours
  • Bile acid sequestrants prevent reabsorption of free THs in the gut (released from conjugated TH metabolites secreted into bile through the enterohepatic circulation). A recommended dose is 4 g of cholestyramine every 6 hours via a nasogastric tube
  • Treat the underlying condition, if any, that precipitated thyroid storm and exclude comorbidities such as diabetic ketoacidosis and adrenal insufficiency. Infection should be treated with antibiotics.
  • Rarely, as a life-saving measure, plasmapheresis has been used to treat thyroid storm in adults. [12]

Iodine preparations should be discontinued once the acute phase resolves and the patient becomes afebrile with normalization of cardiac and neurological status. Glucocorticoids should be weaned and stopped and the dose of thioamides adjusted to maintain thyroid function in the normal range. Beta-blockers may be discontinued once thyroid function normalizes.

If the patient is given PTU during treatment of thyroid storm, this should be switched to methimazole at the time of discharge unless methimazole is contraindicated. If there is a contraindication for the use of methimazole, alternative methods to treat hyperthyroidism should be considered after discharge, such as radioactive iodine or surgery.

Patients with contraindications to thionamides need to be managed with supportive measures, aggressive beta blockade, iodine preparations, glucocorticoids and bile acid sequestrants for about a week in preparation for a thyroidectomy. Plasmapheresis may be attempted if other measures are not effective. 


Surgical Care

Patients with Graves disease who need urgent treatment of hyperthyroidism but have absolute contraindications to thioamides may be treated acutely with beta-blockers, iodine preparations, glucocorticoids, and bile acid sequestrants as described. Plasmapheresis is sometimes used as a last resort if other measures are not effective. Subsequently, thyroidectomy may be performed after about 7 days of iodine administration. Iodine reduces the vascularity of the gland and the risk for thyroid storm.



The following consultations are indicated:

  • Endocrinologist
  • Intensivist


Promptly and appropriately treat thyrotoxicosis after diagnosis. Perform surgery in thyrotoxic patients only after appropriate thyroid and/or beta-adrenergic blockade.

Thyroid storm following radioactive iodine (RAI) therapy for hyperthyroidism may be related to (1) withdrawal of antithyroid medications for RAI administration (usually withdrawn 5-7 d before administration of RAI and held until 5-7 d after RAI therapy), (2) release of large amounts of thyroid hormone from damaged follicles, and (3) RAI itself. Because TH levels are often higher immediately before RAI treatment than they are afterward, many endocrinologists believe that withdrawal of antithyroid drugs is the cause of thyroid storm. One option is to stop antithyroid drugs (including methimazole) only 3 days (rather than 5-7 d) before RAI therapy and to restart antithyroid drugs 3 days after RAI administration. Early institution of antithyroid drugs after RAI therapy may decrease the efficacy of treatment, requiring a second dose.

Consider testing thyroid function before operative procedures in children at high risk for hyperthyroidism (eg, patients with McCune-Albright syndrome).

Contributor Information and Disclosures

Madhusmita Misra, MD, MPH Associate Professor in Pediatrics, Harvard Medical School; Consulting Staff, Fellowship Program Director, Division of Pediatric Endocrinology, Massachusetts General Hospital

Madhusmita Misra, MD, MPH is a member of the following medical societies: American Pediatric Society, American Society for Bone and Mineral Research, Endocrine Society, Pediatric Endocrine Society, Society for Pediatric Research

Disclosure: Nothing to disclose.


Abhay Singhal, MD, MS, MD 

Abhay Singhal, MD, MS, MD is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Deborah E Campbell, MD, FAAP Professor of Clinical Pediatrics, Albert Einstein College of Medicine; Director, Department of Pediatrics, Division of Neonatology, Children's Hospital at Montefiore

Deborah E Campbell, MD, FAAP is a member of the following medical societies: Academic Pediatric Association, American Academy of Pediatrics, American Pediatric Society, American Medical Association, National Perinatal Association, New York Academy of Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Lynne Lipton Levitsky, MD Chief, Pediatric Endocrine Unit, Massachusetts General Hospital; Associate Professor of Pediatrics, Harvard Medical School

Lynne Lipton Levitsky, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Diabetes Association, American Pediatric Society, Endocrine Society, Pediatric Endocrine Society, Society for Pediatric Research

Disclosure: Received grant/research funds from Eli Lilly for pi; Received grant/research funds from NovoNordisk for pi; Received consulting fee from NovoNordisk for consulting; Partner received consulting fee from Onyx Heart Valve for consulting.

Chief Editor

Stephen Kemp, MD, PhD Former Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas for Medical Sciences College of Medicine, Arkansas Children's Hospital

Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Phyllis W Speiser, MD Chief, Division of Pediatric Endocrinology, Steven and Alexandra Cohen Children's Medical Center of New York; Professor of Pediatrics, Hofstra-North Shore LIJ School of Medicine at Hofstra University

Phyllis W Speiser, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, Endocrine Society, Pediatric Endocrine Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

  1. Aiello DP, DuPlessis AJ, Pattishall EG 3rd, Kulin HE. Thyroid storm. Presenting with coma and seizures. In a 3-year-old girl. Clin Pediatr (Phila). 1989 Dec. 28 (12):571-4. [Medline].

  2. Hirvonen EA, Niskanen LK, Niskanen MM. Thyroid storm prior to induction of anaesthesia. Anaesthesia. 2004 Oct. 59(10):1020-2. [Medline].

  3. Kadmon PM, Noto RB, Boney CM, et al. Thyroid storm in a child following radioactive iodine (RAI) therapy: a consequence of RAI versus withdrawal of antithyroid medication. J Clin Endocrinol Metab. 2001 May. 86(5):1865-7. [Medline]. [Full Text].

  4. Alkhuja S, Pyram R, Odeyemi O. In the eye of the storm: iodinated contrast medium induced thyroid storm presenting as cardiopulmonary arrest. Heart Lung. 2013 Jul-Aug. 42(4):267-9. [Medline].

  5. Lawless ST, Reeves G, Bowen JR. The development of thyroid storm in a child with McCune-Albright syndrome after orthopedic surgery. Am J Dis Child. 1992 Sep. 146(9):1099-102. [Medline].

  6. Ono Y, Ono S, Yasunaga H, Matsui H, Fushimi K, Tanaka Y. Factors Associated With Mortality of Thyroid Storm: Analysis Using a National Inpatient Database in Japan. Medicine (Baltimore). 2016 Feb. 95 (7):e2848. [Medline].

  7. Swee du S, Chng CL, Lim A. Clinical characteristics and outcome of thyroid storm: a case series and review of neuropsychiatric derangements in thyrotoxicosis. Endocr Pract. 2015 Feb 1. 21 (2):182-9. [Medline].

  8. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. 1993 Jun. 22(2):263-77. [Medline].

  9. Hasan MK, Tierney WM, Baker MZ. Severe cholestatic jaundice in hyperthyroidism after treatment with 131-iodine. Am J Med Sci. 2004 Dec. 328(6):348-50. [Medline].

  10. Umezu T, Ashitani K, Toda T, Yanagawa T. A patient who experienced thyroid storm complicated by rhabdomyolysis, deep vein thrombosis, and a silent pulmonary embolism: a case report. BMC Res Notes. 2013 May 20. 6(1):198. [Medline]. [Full Text].

  11. US Food and Drug Administration. FDA MedWatch Safety Alerts for Human Medical Products. Propylthiouracil (PTU). Available at Accessed: June 3, 2009.

  12. Petry J, Van Schil PE, Abrams P, Jorens PG. Plasmapheresis as effective treatment for thyrotoxic storm after sleeve pneumonectomy. Ann Thorac Surg. 2004 May. 77(5):1839-41. [Medline].

  13. [Guideline] Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med. 2009. 360(15):1574-5. [Medline]. [Full Text].

  14. Al-Anazi KA, Inam S, Jeha MT, Judzewitch R. Thyrotoxic crisis induced by cytotoxic chemotherapy. Support Care Cancer. 2005 Mar. 13(3):196-8. [Medline].

  15. Knighton JD, Crosse MM. Anesthetic management of childhood thyrotoxicosis and the use of esmolol. Anaesthesia. 1997. 52(1):67-70. [Medline].

  16. Misra M, Levitsky LL, Lee MM. Transient hyperthyroidism in an adolescent with hydatidiform mole. J Pediatr. 2002 Mar. 140(3):362-6. [Medline].

  17. Morrison MP, Schroeder A. Intraoperative identification and management of thyroid storm in children. Otolaryngol Head Neck Surg. 2007 Jan. 136(1):132-3. [Medline].

  18. Ngo AS, Jung Tan DC. Thyrotoxic heart disease. Resuscitation. 2006 Jun 26. [Medline].

  19. Rogers MC, Nichols DG. Thyroid storm. Textbook of Pediatric Intensive Care. Baltimore, MD: Williams & Williams; 1996. 3rd ed: 1291-95.

  20. Sebe A, Satar S, Sari A. Thyroid storm induced by aspirin intoxication and the effect of hemodialysis: a case report. Adv Ther. 2004 May-Jun. 21(3):173-7. [Medline].

  21. Tietgens ST, Leinung MC. Thyroid Storm. Medical Clinics of North America. 1995. 79(1):169-84. [Medline].

  22. Ureta-Raroque SS, Abramo TJ. Adolescent female patient with shock unresponsive to usual resuscitative therapy. Pediatr Emerg Care. 1997 Aug. 13(4):274-6. [Medline].

  23. Wartofsky L. Thyroid storm. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. 6th ed. 1991. 871-79.

  24. Wilson BE, Hobbs WN. Case report: pseudoephedrine-associated thyroid storm: thyroid hormone- catecholamine interactions. Am J Med Sci. 1993 Nov. 306(5):317-9. [Medline].

  25. Yoon SJ, Kim DM, Kim JU, et al. A case of thyroid storm due to thyrotoxicosis factitia. Yonsei Med J. 2003 Apr 30. 44(2):351-4. [Medline].

Pathophysiologic mechanisms of Graves disease relating thyroid-stimulating immunoglobulins to hyperthyroidism and ophthalmopathy. T4 is levothyroxine. T3 is triiodothyronine.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.